Drug Profile

Ebselen - Sound Pharmaceuticals

Alternative Names: DR-3305; Ebselene; Ebseleno; Ebselenum; Harmokisane; PZ-51; SPI-1005; SPI-3005

Latest Information Update: 17 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nattermann
Developer Daiichi Sankyo Company; Medical University of South Carolina; Nattermann; Sound Pharmaceuticals; University of Oxford
Class Anti-ischaemics; Antiasthmatics; Antibacterials; Antiulcers; Antivirals; Azoles; Benzene derivatives; Ear disorder therapies; Ketones; Mood stabilisers; Neuroprotectants; Nonsteroidal anti-inflammatories; Organoselenium compounds; Small molecules; Vascular disorder therapies; Vestibular disorder therapies
Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Glutathione peroxidase stimulants; Leukotriene B4 receptor antagonists; Prostaglandin receptor antagonists; Viral papain like protease inhibitors; Viral protein inhibitors; Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase III Meniere's disease
Phase II Bipolar disorders; COVID 2019 infections; Hearing loss; Noise-induced hearing loss; Sensorineural hearing loss; Tinnitus
No development reported Depressive disorders
Discontinued Asthma; Atherosclerosis; Cerebral infarction; Myocardial ischaemia; Peptic ulcer; Rheumatic disorders

14 Jul 2026 Sound Pharmaceuticals completes enrolment in a phase III trial for Meniere's disease in USA (PO) (NCT06859788),
03 Jun 2026 Sound Pharmaceuticals withdraws prior to enrolment a phase II trial in Hearing loss in the USA (NCT02779192)
01 Jun 2026 Sound Pharmaceuticals withdraws phase II trial prior to enrolment of patients in Sensorineural hearing loss in US (PO) (NCT01451853)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com